UroGen Pharma Ltd. (URGN) SEC Filings & Earnings Calls

Option agreement and early-stage product carry development and regulatory risk.

“Option to obtain license to develop TumoCure product for advanced head and neck cancer.”

JELMYTO revenue decline

“JELMYTO revenue $22.0M vs $24.2M YoY, down 9%”

Generic competition for JELMYTO

“Teva settlement allows generic entry September 15, 2030”

Dependence on ZUSDURI commercial success

“ZUSDURI represents 70% of total revenue”

Product Concentration Risk

“We are highly dependent on the successful commercialization of our approved products, Jelmyto and Zusduri.” · word for word

Capital Requirement Risk

“We have incurred significant losses and negative cash flows since our inception and may not generate positive or sufficient cash flows from operations in the future.” · word for word

Competition Risk

“Jelmyto, Zusduri and our product candidates, if approved, will face significant competition with competing technologies and our failure to compete effectively may prevent us from achieving significant market penetration.” · word for word

Regulatory Risk

“The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about drug products.” · word for word

Shareholder dilution from equity plan expansion.

“1,000,000 additional shares authorized for issuance under equity incentive plan.”

Generic competition risk deferred but not eliminated.

“Teva will be able to sell generic Jelmyto starting Sept 2030.”

Dependence on ZUSDURI launch success; JELMYTO growth modest; pipeline still clinical-stage.

“ZUSDURI revenue $29.2M (109% QoQ) but early stage; JELMYTO growth only 7% YoY; UGN-103 NDA not until H2 2026.”

Dependence on Zusduri and Jelmyto for revenue

“Revenue was $51.0 million and $20.3 million for the three months ended March 31, 2026 and 2025, respectively. The increase in revenue of $30.7 million primarily reflects the volume of sales of Zusduri.” · word for word

Significant accumulated deficit and history of losses

“We have incurred losses since our inception and negative cash flows from our operations, and as of March 31, 2026, we had an accumulated deficit of $983.3 million.” · word for word

Need for additional capital to fund operations

“If we are unable to generate sufficient cash inflows from Jelmyto and Zusduri product sales, we may need to raise additional capital in the future or reduce operating expenditures.” · word for word

Competition from existing standard of care (TURBT)

“The existing standard of care for low-grade intermediate risk NMIBC is a surgical procedure typically performed under general anesthesia called transurethral resection of bladder tumor ("TURBT").” · word for word

Net Loss and Accumulated Deficit

“Net loss of $153.5 million in 2025, accumulated deficit not explicitly stated but implied by losses.”

Dependence on Key Products

“Revenue is concentrated in Jelmyto and newly launched Zusduri; failure of either would materially impact the company.”

Clinical and Regulatory Risk

“Pipeline assets like UGN-103 and UGN-501 are subject to clinical trial and regulatory approval risks.”

Drug Pricing and Reimbursement Pressure

“The current administration has announced agreements with several pharmaceutical companies that require the drug manufacturers to offer, through a direct to consumer platform, U.S. patients and Medicaid programs prescription drug Most-Favored-Nation pricing equal to or lower than those paid in other developed nations, with additional mandates for direct-to-pa” · word for word

Healthcare Coverage Reduction

“On July 4, 2025, the One Big Beautiful Bill Act (the “OBBBA”) was signed into law, which narrowed access to ACA marketplace exchange enrollment and declined to extend the ACA enhanced advanced premium tax credits that expired at the end of 2025, which among other provisions in the law, are anticipated to reduce the number of Americans with health insurance.” · word for word

Dependence on Third-Party Manufacturers

“We do not own or operate manufacturing facilities for the production of Jelmyto and Zusduri or our product candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on third-party contract manufacturers for all of our required raw materials, active ingredients and finished products for Jelmyto ,” · word for word

Competition from Surgical Procedures

“The existing standard of care for low-grade intermediate risk NMIBC is a surgical procedure typically performed under general anesthesia called transurethral resection of bladder tumor (“TURBT”).” · word for word

High Cash Burn Rate

“Net loss $ (153,494 )... As of December 31, 2025, we had $120.5 million in cash and cash equivalents and marketable securities.”

Dependence on ZUSDURI and JELMYTO for revenue; pipeline still clinical-stage.

“Revenue concentrated in two products; pipeline UGN-103/104 still in development.”

Going concern risk due to accumulated losses and negative cash flows

“We have incurred losses since our inception and negative cash flows from our operations, and as of September 30, 2025, we had an accumulated deficit of $933.4 million.” · word for word

Dependence on Zusduri adoption for future revenue growth

“Our ability to continue as a going concern is expected to be impacted by our ability to produce cash inflows from Jelmyto and Zusduri product sales, the rate of physician and patient adoption of Zusduri and our ability to raise additional capital to fund our operations in the future.” · word for word

Potential need for additional capital

“If we are unable to generate sufficient cash inflows from Jelmyto and Zusduri product sales, we may need to raise additional capital in the future or reduce operating expenditures.” · word for word

High operating expenses from Zusduri launch

“Selling and marketing expenses were $23.7 million and $17.8 million for the three months ended September 30, 2025 and 2024, respectively. The increase in selling and marketing expenses of $5.9 million is primarily attributable to Zusduri commercial activities as well as an increase in overall commercial operation costs including the expansion of the sales fo” · word for word

Regulatory and clinical development risks for pipeline candidates

“We cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability.” · word for word

ZUSDURI launch slower than anticipated new patient starts, though demand is accelerating.

“Despite slower than anticipated new patient starts, we are encouraged by the patient demand reflected in our patient enrollment forms.” · word for word

Discontinuation of UGN-301 (zalifrelimab) program after Phase 1; termination of license with Agenus.

“UroGen has made the strategic decision to discontinue development of UGN-301 (zalifrelimab) following completion of its Phase 1 dose escalation study.” · word for word